Evidence map›Paper›PMID 28870080›Full record

ArticleMolecular pharmaceutics2017

Charge Shielding Prevents Aggregation of Supercharged GFP Variants at High Protein Concentration.

Joshua R Laber, Barton J Dear, Matheus L Martins, Devin E Jackson, Andrea DiVenere, Jimmy D Gollihar, Andrew D Ellington, Thomas M Truskett, Keith P Johnston, Jennifer A Maynard

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The N-terminal region of malaria vaccine candidatebioRxiv : the preprint server for biology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Supercharged Phosphotriesterase for improved Paraoxon activity.Protein engineering, design & selection : PEDS · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Structure determinants defining the specificity of papain-like cysteine proteases.Computational and structural biotechnology journal · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joshua R LaberDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.
Barton J DearDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.
Matheus L MartinsDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.
Devin E JacksonDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.
Andrea DiVenereDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.
Jimmy D GolliharDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.
Andrew D EllingtonDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.ORCID 0000-0001-6246-5338
Thomas M TruskettDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.
Keith P JohnstonDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.ORCID 0000-0002-0915-1337
Jennifer A MaynardDepartments of †Chemical Engineering and ‡Molecular Biosciences, University of Texas at Austin , Austin, Texas 78712, United States.ORCID 0000-0002-0363-8486

Funding

Protein nanoclusters for delivery of high concentration therapeutic antibodiesR21AI103763 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI JOHNSTON, KEITH P., MAYNARD, JENNIFER A · 2014 to 2015
$400k
NIAID NIH HHS R21 AI103763
6 · The paper itself

Abstract

Understanding protein stability is central to combatting protein aggregation diseases and developing new protein therapeutics. At the high concentrations often present in biological systems, purified proteins can exhibit undesirable high solution viscosities and poor solubilities mediated by short-range electrostatic and hydrophobic protein-protein interactions. The interplay between protein amino acid sequence, protein structure, and solvent conditions to minimize protein-protein interactions is key to designing well-behaved pharmaceutical proteins. However, theoretical approaches have yet to yield a general framework to address these problems. Here, we analyzed the high concentration behavior of superfolder GFP (sfGFP) and two supercharged sfGFP variants engineered to have formal charges of -18 or +15. Under low cosolute conditions, sfGFP and the -18 variant formed a gel or phase separated at ∼10 mg/mL. Under conditions that screen surface charges, including formulations with high histidine or high NaCl concentrations, all three variants attained concentrations up to 250 mg/mL with moderate viscosities. Moreover, all three variants exhibited very similar viscosity-concentration profiles over this range. This effect was not mimicked by high sugar concentrations that exert excluded-volume effects without shielding charge. Collectively, these data demonstrate that charge shielding neutralizes not only long-range electrostatic interactions but also, surprisingly, short-range electrostatic effects due to surface charge anisotropy. This work shows that supercharged sfGFP behavior under high ionic strength is largely determined by particle geometry, a conclusion that is supported by colloid models and may be applicable to pharmaceutically relevant proteins.

Indexed as

Protein StabilityAnisotropyGreen Fluorescent ProteinsHydrophobic and Hydrophilic InteractionsOsmolar ConcentrationProtein Aggregation, PathologicalProtein ConformationSolubilityStatic ElectricityViscosityGreen Fluorescent Proteinselectrostatic interactionshard sphereprotein aggregationprotein anisotropyviscosity

Identifiers

PMID28870080
PMCPMC5624851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.